Pfizer is reducing its efforts in early-stage rare disease research including the development of viral-based gene therapies, according to a report in Barron’s.
The company is planning to externalize rare disease early-stage research in neurology, cardiology, and its pre-clinical gene therapy programs.
According to the report, the company will sell its gene therapy manufacturing facility in Durham, North Carolina. In December 2021, the company announced it would invest about $70 million in the facility.
Pfizer did not respond to a Rare Daily request for comment as of this posting, but in an emailed response to Fierce Biotech, the company confirmed the Barron’s story.
“We are refocusing our approach to early discovery and development research in rare disease and oncology that involves embedding and continuing certain programs while exploring externalization opportunities for a number of highly innovative, niche programs to maximize the success for these potential medicines,” it told Fierce.
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.